PROSPECTS FOR USING INTERLEUKIN-17 INHIBITORS, A NEW CLASS OF DRUGS FOR TARGETED THERAPY OF PSORIATIC ARTHRITIS
The paradigm of therapy for psoriatic arthritis (PsA) has recently undergone considerable changes due to development and clinical introduction of highly effective targeted drugs based on monoclonal antibodies – inhibitors of different cytokines. The data available in the literature on the possibilit...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2016-07-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2231 |
| _version_ | 1797862693928960000 |
|---|---|
| author | T. V. Korotaeva |
| author_facet | T. V. Korotaeva |
| author_sort | T. V. Korotaeva |
| collection | DOAJ |
| description | The paradigm of therapy for psoriatic arthritis (PsA) has recently undergone considerable changes due to development and clinical introduction of highly effective targeted drugs based on monoclonal antibodies – inhibitors of different cytokines. The data available in the literature on the possibilities of using interleukin 17 (IL-17) inhibitors as a promising PsA therapy were analyzed. The IL-17-mediated signaling pathway was shown to play an important role in both the chronization of synovial inflammation and in the occurrence and development of bone erosions, bone proliferation, and enthesitis in this disease. The combination of the high efficiency and acceptable safety of IL-17 and IL-23 inhibitors could suggest that they might be used as first-line agents for the treatment of PsA or as second-line therapy if tumor necrosis factor-α inhibitors were ineffective or intolerable. The active design of three novel drugs aimed at suppressing IL-17 was noted to only confirm the key role of this cytokine in developing psoriatic disease.The paper gives the data of clinical trials supporting the high efficacy of secukinumab against the key clinical manifestations of PsA. The most important advantage of the drug is the lack of immunogenicity. It is pointed out that the latest edition of the EULAR Guidelines (2015) proposes to include this class of drugs in an algorithm for the treatment of PsA patients. |
| first_indexed | 2024-04-09T22:24:47Z |
| format | Article |
| id | doaj.art-10370d35d880470587742700af0c0bc4 |
| institution | Directory Open Access Journal |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| last_indexed | 2024-04-09T22:24:47Z |
| publishDate | 2016-07-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj.art-10370d35d880470587742700af0c0bc42023-03-22T13:45:51ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922016-07-0154334635110.14412/1995-4484-2016-346-3512105PROSPECTS FOR USING INTERLEUKIN-17 INHIBITORS, A NEW CLASS OF DRUGS FOR TARGETED THERAPY OF PSORIATIC ARTHRITIST. V. Korotaeva0V.A. Nasonova Research Institute of RheumatologyThe paradigm of therapy for psoriatic arthritis (PsA) has recently undergone considerable changes due to development and clinical introduction of highly effective targeted drugs based on monoclonal antibodies – inhibitors of different cytokines. The data available in the literature on the possibilities of using interleukin 17 (IL-17) inhibitors as a promising PsA therapy were analyzed. The IL-17-mediated signaling pathway was shown to play an important role in both the chronization of synovial inflammation and in the occurrence and development of bone erosions, bone proliferation, and enthesitis in this disease. The combination of the high efficiency and acceptable safety of IL-17 and IL-23 inhibitors could suggest that they might be used as first-line agents for the treatment of PsA or as second-line therapy if tumor necrosis factor-α inhibitors were ineffective or intolerable. The active design of three novel drugs aimed at suppressing IL-17 was noted to only confirm the key role of this cytokine in developing psoriatic disease.The paper gives the data of clinical trials supporting the high efficacy of secukinumab against the key clinical manifestations of PsA. The most important advantage of the drug is the lack of immunogenicity. It is pointed out that the latest edition of the EULAR Guidelines (2015) proposes to include this class of drugs in an algorithm for the treatment of PsA patients.https://rsp.mediar-press.net/rsp/article/view/2231psoriatic arthritistumor necrosis factor-αinterleukin 17secukinumabimmunogenicity |
| spellingShingle | T. V. Korotaeva PROSPECTS FOR USING INTERLEUKIN-17 INHIBITORS, A NEW CLASS OF DRUGS FOR TARGETED THERAPY OF PSORIATIC ARTHRITIS Научно-практическая ревматология psoriatic arthritis tumor necrosis factor-α interleukin 17 secukinumab immunogenicity |
| title | PROSPECTS FOR USING INTERLEUKIN-17 INHIBITORS, A NEW CLASS OF DRUGS FOR TARGETED THERAPY OF PSORIATIC ARTHRITIS |
| title_full | PROSPECTS FOR USING INTERLEUKIN-17 INHIBITORS, A NEW CLASS OF DRUGS FOR TARGETED THERAPY OF PSORIATIC ARTHRITIS |
| title_fullStr | PROSPECTS FOR USING INTERLEUKIN-17 INHIBITORS, A NEW CLASS OF DRUGS FOR TARGETED THERAPY OF PSORIATIC ARTHRITIS |
| title_full_unstemmed | PROSPECTS FOR USING INTERLEUKIN-17 INHIBITORS, A NEW CLASS OF DRUGS FOR TARGETED THERAPY OF PSORIATIC ARTHRITIS |
| title_short | PROSPECTS FOR USING INTERLEUKIN-17 INHIBITORS, A NEW CLASS OF DRUGS FOR TARGETED THERAPY OF PSORIATIC ARTHRITIS |
| title_sort | prospects for using interleukin 17 inhibitors a new class of drugs for targeted therapy of psoriatic arthritis |
| topic | psoriatic arthritis tumor necrosis factor-α interleukin 17 secukinumab immunogenicity |
| url | https://rsp.mediar-press.net/rsp/article/view/2231 |
| work_keys_str_mv | AT tvkorotaeva prospectsforusinginterleukin17inhibitorsanewclassofdrugsfortargetedtherapyofpsoriaticarthritis |